# Hardcore Methodological Review (Round 12): Future Frontiers, Feasibility Audits, and Missed Trials

This document registers the transcript of the twelfth-round multiperson adversarial review, detailing out-of-field methodological improvements, a feasibility audit of major cardiology NMAs under our data restrictions, and an analysis of historical trials missed due to our data boundaries.

### Panel Members:
1.  **Dr. Fiona Vance (The Frequentist Purist)**
2.  **Dr. Benjamin MCMC (The Bayesian Pragmatist)**
3.  **Dr. Cynthia Registry (The Clinical Trialist / ct.gov Data Engineer)**

---

## 1. Out-of-Field Methodological Frontiers: Can We Improve Further?

**Dr. Benjamin MCMC (Bayesian):**
> "Yes, by looking outside clinical meta-analysis to **econometrics, finance, and deep learning**, we find three massive frontiers to improve our engine further:
> 
> 1.  **Copula-Based Joint Likelihoods (from Finance/Econometrics):** Efficacy (survival) and safety (adverse events) are modeled separately in NMAs. But they are correlated at the patient level. By implementing **Copulas**, we can model the joint distribution of safety and efficacy dependencies without requiring individual patient data (IPD) for all trials. This is common in financial portfolio risk modeling.
> 2.  **Graph Neural Networks (GNNs) for Missing Contrasts (from Deep Learning):** Instead of static topological regularization, we can treat the treatment network as a graph database and run **inductive GNNs** to predict missing treatment contrasts and learn treatment embeddings.
> 3.  **Variational Autoencoders (VAEs) for IPD Synthesis:** We can train VAEs to generate synthetic patient-level data that matches the aggregate KM statistics and baseline covariate distributions, creating high-fidelity simulated patient cohorts."

---

## 2. Feasibility Audit of Major Cardiology NMAs (Strict Data Boundaries)

We evaluate if the major cardiology NMA domains can be modeled using *only* open-access papers, ct.gov, and PubMed abstracts:

| Cardiology NMA Domain | Key Landmark Trials | Feasibility Status | Limitations and Data Gaps |
|---|---|---|---|
| **SGLT2i in Heart Failure** | DAPA-HF, EMPEROR-Reduced, DELIVER, SOLOIST | **100% Feasible** | All modern trials (post-2018) have open-access curves and complete ct.gov safety tables. |
| **TAVI vs. SAVR** | PARTNER 1/2/3, CoreValve, EVOLUT | **100% Feasible** | High-quality open-access curves exist; long-term time-to-event safety is well-reported. |
| **P2Y12 Monotherapy vs. DAPT** | PLATO, TRITON, TWILIGHT, STOPDAPT-2 | **90% Feasible** | Efficacy KM curves are open access; bleeding events are reported as aggregate tables on ct.gov. |
| **PCSK9i in Hyperlipidemia** | FOURIER, ODYSSEY Outcomes | **80% Feasible** | Efficacy is mostly reported as percentage LDL reduction (continuous), which requires standard GLS meta-regression. |

---

## 3. Did the Heart Failure NMA Miss Trials Due to Data Limitations?

**Dr. Cynthia Registry (Data Engineer):**
> "Yes, the heart failure NMA **missed several critical historical landmark trials** directly because of our strict data boundaries.
> 
> We missed the founding trials of Guideline-Directed Medical Therapy (GDMT):
> *   **SOLVD (1991):** Established ACE inhibitors (Enalapril) vs. Placebo.
> *   **CONSENSUS (1987):** Established ACE inhibitors in severe heart failure.
> *   **RALES (1999):** Established Aldosterone Antagonists (Spironolactone) vs. Placebo.
> *   **MERIT-HF (2000) / CIBIS-II (1999):** Established Beta-Blockers vs. Placebo.
> 
> **Why they were missed:**
> 1.  **Pre-2007 Registry Gap:** These trials were conducted before ClinicalTrials.gov results reporting was legally mandated by the FDAAA in 2007. They have no structured registry results pages.
> 2.  **Paywall Boundaries:** Original publications are from the 1980s and 1990s. They are locked behind paywalls (not open access) and are often low-resolution scanned PDFs, making vector curve extraction impossible.
> 3.  **Cochrane / Abstract Limitations:** While PubMed abstracts list point estimates, they lack the detailed arm-level event counts and sample sizes needed for exact binomial likelihoods and quality adjustments."

**Dr. Fiona Vance (Frequentist):**
> "This data missingness introduces a **historical transitivity bias** in our network. Because we cannot connect the modern treatments (SGLT2i, ARNI) to the historical placebo baselines of the 1990s, we must rely on ARB or modern standard-of-care as the reference baseline, which differs from the raw placebo of the ACE-inhibitor era."
